Compare PGEN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | RCUS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2013 | 2018 |
| Metric | PGEN | RCUS |
|---|---|---|
| Price | $4.21 | $15.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $13.67 | ★ $40.92 |
| AVG Volume (30 Days) | ★ 6.8M | 1.9M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | $230,981,000.00 | ★ $247,000,000.00 |
| Revenue This Year | $2,380.31 | N/A |
| Revenue Next Year | $84.01 | N/A |
| P/E Ratio | $34.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.04 | $15.65 |
| 52 Week High | $8.98 | $31.74 |
| Indicator | PGEN | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 28.46 |
| Support Level | $3.89 | N/A |
| Resistance Level | $4.41 | $24.80 |
| Average True Range (ATR) | 0.36 | 0.97 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 16.78 | 1.23 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.